At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 512 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase
In Brief
A Phase 3 clinical trial evaluating Apixaban and No systemic anticoagulant prophylaxis for Lymphoma and Acute Lymphoblastic Leukemia. Completed, enrolled 512 participants across 96 sites in 12 countries.
Detailed Summary
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Acute Lymphoblastic Leukemia
CountriesAustralia, Belgium, Canada, Czechia, Hungary, Mexico, New Zealand, Poland, Puerto Rico, Russia, South Korea, United States
CollaboratorsPfizer
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartOct 2015
Primary CompletionJul 2021
TodayJul 2026
First PostedFeb 24, 2015
Enrollment StartOct 22, 2015
Primary CompletionJul 7, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.4 years ago
Interventions
Apixabandrug
No systemic anticoagulant prophylaxisother